JAK2 and ventilator-associated pneumonia: If unresolving episodes of VAP, rather than the primary viral pneumonia, contribute to mortality in a substantial fraction of patients with severe SARS-CoV-2 pneumonia, it might explain why therapies that attenuate the host response (e.g., corticosteroids, IL-6 receptor antagonists, JAK2 inhibitors, and calcium release–activated calcium [CRAC] channel inhibitors) are more effective when administered early in the clinical course, before patients are intubated and at risk for VAP (1, 34, 42–44).